Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Xp22.3 microdeletion syndrome is a microdeletion syndrome resulting from a partial deletion of the chromosome X. Phenotype is highly variable (depending on length of deletion), but is mainly characterized by X linked ichthyosis, mild-moderate intellectual deficit, Kallmann syndrome, short stature, chondrodysplasia punctata and ocular albinism. Epilepsy, attention deficit-hyperactivity disorder, autism and difficulties with social communication can be associated.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for Xp22.3 microdeletion syndrome.
1 publication has been identified in PubMed for Xp22.3 microdeletion syndrome. Research spans Review / Meta-Analysis (100%).
Fryze M (2026). [PMID: 41743903](https://pubmed.ncbi.nlm.nih.gov/41743903/). *Clin Cosmet Investig Dermatol*. [Review / Meta-Analysis]
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 1:03 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Xp22.3 microdeletion syndrome